Arax Advisory Partners
CRVS icon

Arax Advisory Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Arax Advisory Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12K Buy
+75
New +$1.04K ﹤0.01% 4919
2026
Q1 		– Sell
-10
Closed -$77 – 3910
2025
Q4 		$77 Sell
10
-136
-93% -$1.07K ﹤0.01% 3866
2025
Q3 		$1.08K Buy
+146
New +$747 ﹤0.01% 3242

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arax Advisory Partners's CRVS Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 75 shares worth $1.12K. The stake represents ﹤0.01% of the portfolio and ranks #4919 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in CRVS as recently as Q4 2025.

Arax Advisory Partners first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Arax Advisory Partners held 75 shares of Corvus Pharmaceuticals worth $1.12K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4919 holding.
  • Arax Advisory Partners first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.